Institut National De La Sante Et De La Recherche Medicale

Université Paris Diderot-paris 7

Assistance Publique-hopitaux De Paris

Universitè De Montpellier

Institut Regional Du Cancer De Montpellier

Université De Paris

Université De Versailles—saint-quentin-en-yvelines

Université Paris Diderot

Inserm

Thierry Voisin

Alain Couvineau

Pascal Nicole

Bruno Robert

Pierre Martineau

Myriam Chentouf

Eric Ogier-Denis

Xavier Treton

Nassima Messal

Valérie Gratio

Anne Couvelard

The present invention relates to methods and pharmaceutical compositions for the treatment of cancer. More particularly, the present invention relates to a method of treating cancer in subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one OX1R antagonist.

Methods and pharmaceutical compositions for the treatment of cancer

The present disclosure relates to human monoclonal antibodies against orexin receptor type 1 (OX1R, hyprocretin 1) and uses thereof for the treatment of cancer. The antibodies are characterized by their CDRs: NYYMN, YISGSSRNIYYADFVKG, SNYDGMDV (Heavy chain) and AGTSSDVGGSNYVS, PGKAP, SSYTYYSTRV (Light Chain)) or the CDRS having at least 50% or 70% identity with the above listed sequences.

Human monoclonal antibodies against orexin receptor type 1

The present invention relates to methods and pharmaceutical compositions for the treatment of inflammatory bowel diseases. The presents methods relates to a method of treating an inflammatory bowel disease in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one OX1R agonist.

Method of treating an inflammatory bowel disease comprising agonists of orexin-1 receptor

Growing community of inventors

Paris, France

Thierry Voisin